Abstract
The low-resource environment deprives healthcare providers caring for patients with Ebola virus disease (EVD) of many of the means employed for the critically ill that are available in better resourced settings, such as advanced therapeutic interventions and abundant staff. In addition to these limitations may be added those imposed by the remote tropical locations, where EVD outbreaks occur. In this setting, a safe environment is created where healthcare workers may care for their patients over the evolving course of their acute illness into their convalescent period. Clinical management of EVD combines supportive and symptomatic care while also addressing the patient’s emotional and mental health needs. A variety of specific therapies directly targeting the virus has become available, but none of these has, as of yet, conclusively demonstrated an impact. Healthcare workers caring for EVD patients must be constantly aware that they are part of a larger epidemic control operation, and their actions have consequences that go beyond their patients to their families and the community affected by the outbreak.
References
Bray M, Chertow D (2016) Filoviruses. In: Richman D, Whitley R, Hayden F (eds) Clinical virology, 4th edn. ASM Press, Washington, DC, pp 1–28
Caluwaerts S, Fautsch T, Lagrou D (2016) Dilemmas in managing pregnant women with Ebola: 2 case reports. Clin Infect Dis 62(7):903–905
Davey RT, The Multi-National PREVAIL II Study Team (2016) PREVAIL II: A randomized controlled trial of ZMapp™ in Acute Ebola virus infection. Presented at the conference on retroviruses and opportunistic infections, Boston, 22–25 Feb 2016
Dellinger RP, Levy MM, Rhodes A (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41(2):580–637
Dörnemann J, Burzio C, Ronsse A et al (2017) First newborn baby to receive experimental therapies survives Ebola virus disease. J infect Dis 215(2):171–174
Dunning J, Sahr F, Rojek A et al (2016) Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med 13(4):e1001997
Emond RT, Evans B, Bowen ET et al (1977) A case of Ebola virus infection. Br Med J 2:541–544
Evlampidou I, Rabelo I, Lee V (2016) Psychological suffering among Ebola virus disease survivors in Monrovia, Liberia: a mixed methods study. Front Public Health 4:142
Henao-Restrepo AM, Longini IM, Egger M et al (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386(9996):857–866
Howlett P, Brown C, Helderman T (2016) Ebola virus disease complicated by late-onset encephalitis and polyarthritis, Sierra Leone. Emerg Infect Dis 22(1):150–152
International Food Policy Research Institute (IFPRI) (2016) Global nutrition report 2016: from promise to impact: ending malnutrition by 2030. Washington, DC
Jacobs M, Rodger A, Bell DJ (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388(10043):498–503
Kortepeter MG, Bausch DG, Bray M (2011) Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 204(Suppl 3):S810–S816
Kreuels B, Wichmann D, Emmerich P et al (2014) A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 371(25):2394–2401
Maganga GD, Kapetshi J, Berthet N et al (2014) Ebola virus disease in the Democratic Republic of Congo. N Engl J Med 371(22):2083–2091
Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4(8):487–498
Maitland K, Kiguli S, Opoka RO et al (2011) Mortality after fluid bolus in African Children with severe infection. N Engl J Med 364(26):2483–2495
Marais F, Minkler M, Gibson N (2016) A community-engaged infection prevention and control approach to Ebola. Health Promot Int 31(2):440–449
Marik P, Bellomo R (2016) A rational approach to fluid therapy in sepsis. Br J Anaesth 116(3):339–349
Martini GA, Schmidt HA (1968) Spermatogenic transmission of the “Marburg virus”: causes of “Marburg simian disease”. Klin Wochenschr 46:398–400 (In German)
Mate SE, Kugelman JR, Nyenswah TG et al (2015) Molecular evidence of sexual transmission of Ebola virus. N Engl J Med 373(25):2448–2454
McElroy A (2015) Understanding bleeding in Ebola virus disease. Clin Adv Hematol Oncol 13(1):29–31
Mupapa K, Mukundu W, Bwaka MA et al (1999a) Ebola hemorrhagic fever and pregnancy. J Infect Dis 179(Suppl 1):S11–S12
Mupapa K, Massamba M, Kibadi K et al (1999b) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179(Suppl 1):S18–S23
The National Institute for Occupational Safety and Health (NIOSH) (2015) Hierarchy of controls. https://www.cdc.gov/niosh/topics/hierarchy/. Accessed 10 Aug 2016
Rabelo I, Lee V, Fallah MP et al (2016) Psychological distress among Ebola survivors discharged from an Ebola treatment unit in Monrovia, Liberia—a qualitative study. Front Public Health 4(142)
Rollin PE, Bausch DG, Sanchez A (2007) Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 196(Suppl 2):S364–S371
Sissoko D, Laouenan C, Folkesson E et al. (2016) Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 13(3). doi:10.1371/journal.pmed.1001967
Spengler JR, McElroy AK, Harmon JR et al (2015) Relationship between Ebola virus real-time quantitative polymerase chain reaction-based threshold cycle value and virus isolation from human plasma. J Infect Dis 212(Suppl 2):S98–S100
Sprecher AG, Caluwaerts A, Draper M et al (2015) Personal protective equipment for filovirus epidemics: a call for better evidence. J Infect Dis 212(Suppl 2):S346–S349
United Nations, Department of Economic and Social Affairs, Population Division (2015) World population prospects: the 2015 revision. https://esa.un.org/unpd/wpp/. Accessed 10 Aug 2016
van Griensven J, Edwards T, de Lamballerie X et al (2016) Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374(1):33–42
Vetter P, Kaiser L, Schibler M et al (2016) Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis 16(6):e82–e91
Wamala JF, Lukwago L, Malimbo M et al (2010) Ebola hemorrhagic fever associated with novel virus strain Uganda 2007-2008. Emerg Infect Dis 16(7):1087–1092
WHO/UNICEF/WFP (2014) Interim guideline: nutritional care of children and adults with Ebola virus disease in treatment centres. Geneva, Switzerland
Wong KK, Perdue CL, Malia J et al (2015) Monrovia medical unit. Supportive care of the first 2 Ebola virus disease patients at the Monrovia medical unit. Clin Infect Dis 61(7):e47–e51
World Health Organization (2014) Case definition recommendations for Ebola or Marburg virus diseases. http://www.who.int/csr/resources/publications/ebola/case-definition/en/. Accessed 10 Aug 2016
World Health Organization (WHO) (2016) Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. Geneva, Switzerland
Disclaimer
The findings and conclusions in this chapter are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Sprecher, A., Van Herp, M., Rollin, P.E. (2017). Clinical Management of Ebola Virus Disease Patients in Low-Resource Settings. In: Mühlberger, E., Hensley, L., Towner, J. (eds) Marburg- and Ebolaviruses. Current Topics in Microbiology and Immunology, vol 411. Springer, Cham. https://doi.org/10.1007/82_2017_18
Download citation
DOI: https://doi.org/10.1007/82_2017_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68946-3
Online ISBN: 978-3-319-68948-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)